Stockreport

Travere Therapeutics price target lowered to $30 from $32 at Scotiabank [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF The company recently presented updated data for its Filspari in IgA nephropathy and focal segmental glomerulosclerosis, reiterating the drug's “robust clinical profile,” [Read more]